Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
BIBioVie Inc. logo

BioVie Inc. (BIVI)

NASDAQ Capital Market · Currency in USD
$1.24 ▼ -0.04 (-3.13%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.22 ▼ -0.02 (-1.90%)
Pre-market: Oct 26, 7:29 AM ET

Summary

Previous Close
$1.28
Open
$1.27
Day's Range
$1.23 – $1.30
52 Week Range
$0.82 – $3.79
Volume
141,650
Avg. Volume
3,267,392
Market Cap
$10.77M
Beta (5Y Monthly)
0.73
PE Ratio (TTM)
--
EPS (TTM)
-$2.93
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: BioVie Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
13
CEO
Cuong Viet Do

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease.

Earnings

Next report: Mon, Nov 9, 2026
DateEst.Actual
Aug 12, 2026-$0.52-$0.70Miss
May 11, 2026-$0.73-$0.70Beat
Feb 10, 2026-$0.81-$0.77Beat
Nov 10, 2025-$0.79-$0.98Miss
Aug 15, 2025-$1.82-$1.82Beat
May 12, 2025-$3.20-$1.50Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on BIVI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.